PCRI is a 501(c) (3)
Not-for-profit public charity
To Learn More:
PCRI Mission
PCRI Staff & Boards
New to PCRI
Basics of PC
Undiagnosed
Newly Diagnosed
Local Therapies
Systemic Therapies
Androgen Independent
High Risk PC
Treatment Side-Effects
Software & Forms
Resources & Links
Donate Helpline Decision
Aide About
Us Español 
Newsletter PCRI
Papers Resources Search
PCRI is pleased to provide general prostate cancer news items courtesy of CancerConsultants.com Inc. whose mission is “to empower patients with current information on all aspects of the management of Prostate Cancer in order to provide support and hope, as well as to facilitate informed decisions”.
General Prostate Cancer News Archives
News By Topic
Prostate Cancer - Screening/PreventionProstate Cancer - Early Stage I-II (A-B)Finasteride May Prevent Prostate Cancer Without Increased Risk of Aggressive Cancers (6/26/2008)
Treatment with finasteride for seven years reduced the incidence of prostate cancer by approximately 25% without increasing the incidence of aggressive prostate cancers. These findings, which included a reanalysis of previously reported results, were published in Cancer Prevention Research.Specific Gene Expression Predicts Risk for Prostate Cancer (5/5/2008)
Expression of the PTOV1 gene helps predict the likelihood of the development of prostate cancer among men with high-grade prostatic intraepithelial neoplasia (HG-PIN). These results were recently published in the journal Clinical Cancer Research.Fluctuation in Weight May Influence Risk for Prostate Cancer (4/9/2008)
A large study conducted in Austria reveals that large weight gains or losses may influence an individual’s risk for developing certain types of cancer, including prostate cancer. Complete details of the study were published in the Annals of Oncology.Internet May Be Useful Tool for Education About Prostate Cancer (3/10/2008)
Public health Web sites may not be as useful to men concerned about prostate cancer as educational online presentations about the disease. This recent study was published in the Archives of Internal Medicine.Testosterone Levels Not Associated with Risk of Prostate Cancer (1/30/2008)
According to an article recently published in the Journal of the National Cancer Institute, testosterone levels do not appear to be associated with risk of developing prostate cancer.Prostate Cancer - Locally Advanced Stage III (C)Denosumab Improves Bone Density in Prostate Cancer Patients (7/14/2008)
In a Phase III clinical trial among men receiving androgen-deprivation therapy for nonmetastatic prostate cancer, treatment with investigational drug denosumab improved bone density and reduced the risk of vertebral fractures.Immediate Hormone Therapy May Not Improve Outcomes in Elderly Men with Prostate Cancer (7/10/2008)
Treatment with immediate hormone therapy may not improve outcomes compared with conservative management among elderly men with prostate cancer. These results were recently published in the Journal of the American Medical Association.Updates in the Management of Prostate and Kidney Cancers (5/6/2008)
A report from the 2008 ASCO Genitourinary Cancers SymposiumChanges in Lifestyle May Improve Quality of Life for Prostate Cancer Survivors (5/5/2008)
A recent study conducted by the American Cancer Society reports that although few cancer survivors follow recommendations for lifestyle changes aimed to improve health and well-being, adhering to these guidelines may improve quality of life among prostate cancer survivors. Full details of the study were recently published in the Journal of Clinical Oncology.Satisfaction with Treatment Outcome Reflects Quality of Life Among Prostate Cancer Survivors (3/28/2008)
A recent study indicates that prostate cancer treatment may be associated with changes in quality of life that impact satisfaction with treatment outcomes for both patients and their spouses or partners. These findings were published in the New England Journal of Medicine.Prostate Cancer - Metastatic Stage IV (D)Denosumab Improves Bone Density in Prostate Cancer Patients (7/14/2008)
In a Phase III clinical trial among men receiving androgen-deprivation therapy for nonmetastatic prostate cancer, treatment with investigational drug denosumab improved bone density and reduced the risk of vertebral fractures.Fareston® Decreases Spinal Fractures in Men with Prostate Cancer (6/10/2008)
Among prostate cancer patients receiving androgen deprivation therapy (ADT), treatment with Fareston® (toremifene citrate) reduces the risk of new spinal fractures. These results were presented at the 2008 annual meeting of the American Association for Cancer Research.Updates in the Management of Prostate and Kidney Cancers (5/6/2008)
A report from the 2008 ASCO Genitourinary Cancers SymposiumChanges in Lifestyle May Improve Quality of Life for Prostate Cancer Survivors (5/5/2008)
A recent study conducted by the American Cancer Society reports that although few cancer survivors follow recommendations for lifestyle changes aimed to improve health and well-being, adhering to these guidelines may improve quality of life among prostate cancer survivors. Full details of the study were recently published in the Journal of Clinical Oncology.Satisfaction with Treatment Outcome Reflects Quality of Life Among Prostate Cancer Survivors (3/28/2008)
A recent study indicates that prostate cancer treatment may be associated with changes in quality of life that impact satisfaction with treatment outcomes for both patients and their spouses or partners. These findings were published in the New England Journal of Medicine.Prostate Cancer - Refractory/RecurrentRadiofrequency Ablation Effective for Lung Tumors (7/16/2008)
The use of radiofrequency ablation for the treatment of lung cancer, or pulmonary metastases (cancer that has spread from site of origin to the lung) provides an effective and safe therapeutic option for some patients. These results were recently published in the Lancet Oncology.Bone Marker Associated with Survival in Breast, Prostate, and Lung Cancers (6/23/2008)
The bone marker N-telopeptide of type I collagen (NTX) is associated with skeletal-related events and survival among patients with cancer that has spread to the bone (bone metastases). Improved outcomes may be achieved by reducing these markers through treatment with agents such as Zometa® (zoledronic acid). These results were recently published in the journal Cancer.Fareston® Decreases Spinal Fractures in Men with Prostate Cancer (6/10/2008)
Among prostate cancer patients receiving androgen deprivation therapy (ADT), treatment with Fareston® (toremifene citrate) reduces the risk of new spinal fractures. These results were presented at the 2008 annual meeting of the American Association for Cancer Research.Changes in Lifestyle May Improve Quality of Life for Prostate Cancer Survivors (5/5/2008)
A recent study conducted by the American Cancer Society reports that although few cancer survivors follow recommendations for lifestyle changes aimed to improve health and well-being, adhering to these guidelines may improve quality of life among prostate cancer survivors. Full details of the study were recently published in the Journal of Clinical Oncology.Family Intervention Helps Spouses of Prostate Cancer Patients (11/15/2007)
According to the results of a study published in the journal Cancer, a family intervention that offered support and information to prostate cancer patients and their spouses provided important benefits, particularly to the spouses.Radiofrequency Ablation Effective for Lung Tumors (7/16/2008)
The use of radiofrequency ablation for the treatment of lung cancer, or pulmonary metastases (cancer that has spread from site of origin to the lung) provides an effective and safe therapeutic option for some patients. These results were recently published in the Lancet Oncology.Bone Marker Associated with Survival in Breast, Prostate, and Lung Cancers (6/23/2008)
The bone marker N-telopeptide of type I collagen (NTX) is associated with skeletal-related events and survival among patients with cancer that has spread to the bone (bone metastases). Improved outcomes may be achieved by reducing these markers through treatment with agents such as Zometa® (zoledronic acid). These results were recently published in the journal Cancer.Salvage Radiotherapy Improves Prostate Cancer-specific Survival (6/20/2008)
Radiation therapy following a recurrence of prostate cancer may reduce deaths specifically caused by the disease. These results were recently published in the Journal of the American Medical Association.Updates in the Management of Prostate and Kidney Cancers (5/6/2008)
A report from the 2008 ASCO Genitourinary Cancers SymposiumGVAX® Promising for Recurrent Prostate Cancer (4/21/2008)
The immunotherapeutic vaccine GVAX® provides promising activity in patients with recurrent prostate cancer. These results were recently presented at the 2008 annual meeting of the American Association for Cancer Research.
Copyright ©2005 CancerConsultants.com. All Rights Reserved.
Latest General Prostate Cancer News
Prostate Cancer Research Institute (PCRI)
Material provided by PCRI is intended for educational purposes for discussion with your physician and should not be considered as medical advice. Information and opinions expressed on this website are not an endorsement by PCRI for any treatment, product or service.